Search company, investor...
c-LEcta company logo


Founded Year



Corporate Majority | Acquired

Total Raised




About c-LEcta

c-LEcta is a fully integrated biotechnology company focused on enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries.On February 15th, 2022, Kerry Group acquired a majority stake in c-LEcta for $155.34M.

Headquarters Location

Perlickstr. 5

Leipzig, 04103,



Missing: c-LEcta's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: c-LEcta's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing c-LEcta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

c-LEcta is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

c-LEcta Patents

c-LEcta has filed 1 patent.

The 3 most popular patent topics include:

  • Enzymes
  • EC 2.4.1
  • EC 3.2.1
patents chart

Application Date

Grant Date


Related Topics




EC 2.4.1, Enzymes, EC 3.2.1, Protein domains, Molecular biology


Application Date


Grant Date



Related Topics

EC 2.4.1, Enzymes, EC 3.2.1, Protein domains, Molecular biology



Latest c-LEcta News

c-LEcta: OFB Starts Construction Work for “BioSquare Leipzig” Technology Campus

Sep 23, 2022

Download From left to right: Dr. Marc Struhalla (CEO of c-LEcta GmbH), Dr. Christoph Wiechmann (OFB Leipzig) and Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig). From left to right: Dr. Marc Struhalla (CEO of c-LEcta GmbH), Dr. Christoph Wiechmann (OFB Leipzig) and Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig). September 23, 2022 03:35 AM Eastern Daylight Time FRANKFURT, Germany--( BUSINESS WIRE )--OFB Projektentwicklung has started the first construction phase of the “BioSquare Leipzig” on a partial area of around 11,600 m² of the construction site 6a on the street “Alte Messe.” The symbolic groundbreaking ceremony on September 22, 2022, took place in the presence of Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig), Dr. Marc Struhalla (CEO of c-LEcta GmbH) and Dr. Christoph Wiechmann (Office Manager for Leipzig at OFB Projektentwicklung). The ceremony marks the start of a modern campus for biotechnology and the life sciences that comprises several buildings. The excavation of around 35,000 m³ of soil is scheduled to be completed by mid-November this year. As early as February 2022, a facade competition was held for the project with five architectural firms and a jury consisting of politicians, architects, scientists, the tenant c-LEcta and OFB. The Leipzig-based firm KLM Architekten und Ingenieure GmbH has now been commissioned as building planner for the first construction phase with the facade design. Above ground, the first construction phase consists of two independent buildings with a total of around 18,500 m² of rental space. Five floors are planned for Building A, which will be used by the biotechnology company c-LEcta GmbH in the future and will have around 10,500 m² of above-ground rental space. c-LEcta has been located at the “Alte Messe” site since the company was founded in 2004, and moved into its headquarters in the BioCube in 2012. The company has changed significantly since then: What began as a university spin-off with five employees has now evolved into a leading global player in industrial biotechnology. In 2021, c-LEcta worked with over 400 customers from more than 40 countries in the food and pharmaceutical industries, and once again significantly increased its sales compared to the previous year. Along with this, the number of employees has also developed rapidly over the years. Since 2018 alone, the number has doubled to 120 employees. Further growth in the workforce is also planned in the years ahead, so there will not be enough space available for the office and laboratory space in the current building. The neighboring Building B in the direction of Prager Strasse comprises seven stories and thus offers a view over the old trade fair grounds after their completion. The slight offset of the second building will create a forecourt that provides an inviting access to building B with a good quality stay. Furthermore, a shared underground parking garage with around 110 parking spaces is being built. Construction work on c-Lecta’s new corporate headquarters is scheduled for completion in the first half of 2025. In the second building of the first construction phase, another 8,000 m² of rental space is being created. With floor heights of four meters and modern construction grids, both buildings offer maximum flexibility in terms of use, so that both office space and laboratory space can be realized. “The BioSquare project development underscores Leipzig’s importance as an innovation center for biotechnology and the life sciences. We want to keep innovative companies in these future industries at the location and attract new ones. Of course, we are particularly pleased that c-LEcta, a Leipzig success story, is moving into the first construction phase,” said the mayor and alderman for Urban Development and Construction of the City of Leipzig, Thomas Dienberg. “The groundbreaking ceremony for our new headquarters in Leipzig is obviously a very special moment. In 2025, we will move into a high-tech building here with state-of-the-art workplaces and laboratories. This will not only secure sufficient space for further development in the long term, but at the same time provide a state-of-the-art design concept for our employees. Collaboration, concentrated work and regeneration go hand in hand. We are pleased to be able to continue our history at our home location,” emphasized Dr. Marc Struhalla, CEO of the tenant c-LEcta. Dr. Christoph Wiechmann, head of OFB’s Leipzig office, is also quite pleased: “It is great to see that the excavators are now turning and the realization phase of BioSquare has begun. The ‘Alte Messe’ has made a name for itself as a location for innovative companies. On our campus, we offer research institutions and technology companies completely new development opportunities and perfect framework conditions.” The project site is located within sight of the well-known double M of the Leipzig Mustermesse. The neighboring S-Bahn station “Völkerschlachtdenkmal” as well as several streetcar and bus lines offer very good public transport connections. The freeway ring road can also be reached in less than five minutes. Several innovative research institutions and companies such as the Fraunhofer IZI, the Max Planck Institute, Bio-City or the German Center for Integrative Biodiversity Research (iDiv) have settled at the “Alte Messe” location in recent years. OFB: WE CONTINUE TO DEVELOP. OFB Projektentwicklung GmbH has been in the real estate business for over 60 years. And is still as committed as on the first day. As a subsidiary of Landesbank Hessen-Thüringen and part of the Helaba Immobiliengruppe, high-quality and sustainable large-scale real estate is our focus. Project development, project management and real estate management are our passion. At our headquarters in Frankfurt/Main and in our branches in Berlin, Erfurt, Munich, Düsseldorf and Leipzig, around 140 employees realize successful real estate projects throughout Germany. In doing so, we want to work harder than others – and therefore take the interaction of economic, ecological and social components into account as early as the planning stage of our projects. The goal: to develop our projects further, and ourselves as well. About c-LEcta c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 120 people at its headquarters in Leipzig. c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet. Contacts

c-LEcta Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

c-LEcta Rank

c-LEcta Frequently Asked Questions (FAQ)

  • When was c-LEcta founded?

    c-LEcta was founded in 2004.

  • Where is c-LEcta's headquarters?

    c-LEcta's headquarters is located at Perlickstr. 5, Leipzig.

  • What is c-LEcta's latest funding round?

    c-LEcta's latest funding round is Corporate Majority.

  • How much did c-LEcta raise?

    c-LEcta raised a total of $530K.

  • Who are the investors of c-LEcta?

    Investors of c-LEcta include Kerry Group, Capricorn Partners, bm-t beteiligungsmanagement thuringen, Horizon 2020, High-Tech Grunderfonds and 3 more.

  • Who are c-LEcta's competitors?

    Competitors of c-LEcta include Cathay Industrial Biotech, Fyodor Biotechnologies, Catalyst Biosciences, Iverson Genetic Diagnostics, Calibrant Biosystems and 13 more.

Compare c-LEcta to Competitors

Biolog Logo

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.


Excelsyn integrate specialist management consulting, chemistry and engineering to offer a range of solutions that can enhance performance across the whole pharmaceuticals, biotech and chemicals value chain.

Laureate Pharma

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.

Plexus Ventures Logo
Plexus Ventures

The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies


VANADIS is focused on research and consultant activity, such as custom synthesis of organic and polymeric compounds. The preparation of lactic acid biodegradable polymers for biomedical applications, that relies on the company's long experience, is a key point within VANADIS activities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.